Processa Pharmaceuticals Stock Performance
| PCSA Stock | USD 0.53 0.03 5.36% |
The company holds a Beta of -0.65, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Processa Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Processa Pharmaceuticals is likely to outperform the market. At this point, Processa Pharmaceuticals has a negative expected return of -1.15%. Please make sure to check Processa Pharmaceuticals' potential upside and the relationship between the accumulation distribution and price action indicator , to decide if Processa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:20 | Dividend Date 2019-12-23 | Last Split Date 2024-01-22 |
1 | Acquisition by Pannu Geraldine of 4500 shares of Processa Pharmaceuticals at 0.21 subject to Rule 16b-3 | 12/05/2024 |
2 | Processa Pharmaceuticals stock hits 52-week low at 0.85 - Investing.com | 12/20/2024 |
3 | Processa Pharmaceuticals stock hits 52-week low at 0.8 - Investing.com | 01/17/2025 |
4 | Processa Pharmaceuticals Announces Pricing of 5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 01/28/2025 |
5 | Processa Pharmaceuticals director David Young buys 99,288 in stock - Investing.com | 01/29/2025 |
6 | Processa Pharmaceuticals Announces Closing of 5 Million Public Offering Priced At-The-Market ... | 01/30/2025 |
7 | Processa Pharmaceuticals to Present at the 2025 BIO CEO Investor Conference | 02/07/2025 |
8 | Processa Pharmaceuticals, Inc. Among the Cheapest Stocks Insiders Are Buying Recently | 02/21/2025 |
| Begin Period Cash Flow | 6.5 M |
Processa |
Processa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 116.00 in Processa Pharmaceuticals on November 29, 2024 and sell it today you would lose (63.00) from holding Processa Pharmaceuticals or give up 54.31% of portfolio value over 90 days. Processa Pharmaceuticals is currently does not generate positive expected returns and assumes 5.9396% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Processa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Processa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Processa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Processa Pharmaceuticals, and traders can use it to determine the average amount a Processa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1935
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCSA |
Estimated Market Risk
| 5.94 actual daily | 52 52% of assets are less volatile |
Expected Return
| -1.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Processa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Processa Pharmaceuticals by adding Processa Pharmaceuticals to a well-diversified portfolio.
Processa Pharmaceuticals Fundamentals Growth
Processa Stock prices reflect investors' perceptions of the future prospects and financial health of Processa Pharmaceuticals, and Processa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Processa Stock performance.
| Return On Equity | -2.12 | ||||
| Return On Asset | -1.13 | ||||
| Current Valuation | (203.32 K) | ||||
| Shares Outstanding | 4.74 M | ||||
| Price To Book | 0.70 X | ||||
| EBITDA | (11.46 M) | ||||
| Net Income | (11.12 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 150.55 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 1.14 X | ||||
| Cash Flow From Operations | (8.06 M) | ||||
| Earnings Per Share | (5.02) X | ||||
| Market Capitalization | 2.59 M | ||||
| Total Asset | 5.79 M | ||||
| Retained Earnings | (75.37 M) | ||||
| Working Capital | 4.9 M | ||||
About Processa Pharmaceuticals Performance
By analyzing Processa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Processa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Processa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Processa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 643.99 | 344.59 | |
| Return On Tangible Assets | (1.73) | (1.82) | |
| Return On Capital Employed | (2.61) | (2.74) | |
| Return On Assets | (1.73) | (1.82) | |
| Return On Equity | (2.56) | (2.69) |
Things to note about Processa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Processa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Processa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Processa Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Processa Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (11.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (8.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Processa Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Processa Pharmaceuticals, Inc. Among the Cheapest Stocks Insiders Are Buying Recently |
- Analyzing Processa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Processa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Processa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Processa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Processa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Processa Pharmaceuticals' stock. These opinions can provide insight into Processa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |